Additional postdilatation using noncompliant balloons after everolimus-eluting stent implantation: Results of the PRESS trial
- Author(s)
- Gyung‐Min Park; Jae‐Hwan Lee; Si Wan Choi; Jin‐Ok Jeong; Eun‐Seok Shin; Jang‐Whan Bae; Hyuck‐Jun Yoon; Kyung Tae Jung; Ju Yeol Baek; Woong Gil Choi; Rak Kyeong Choi; Sung‐Ho Her; Jin Bae Lee; Jon Suh; Jae Beom Lee; Se‐Whan Lee; In‐Ho Chae; So‐Yeon Choi; In‐Whan Seong
- Keimyung Author(s)
- Yoon, Hyuck Jun
- Department
- Dept. of Internal Medicine (내과학)
- Journal Title
- Clinical cardiology
- Issued Date
- 2020
- Volume
- 43
- Issue
- 6
- Keyword
- drug‐eluting stent; everolimus‐eluting stent; noncompliant balloon; postdilatation
- Abstract
- Background:
There are limited data on the clinical value of routine postdilatation using noncompliant balloons after contemporary drug‐eluting stent implantation.
Hypothesis:
Additional postdilatation using noncompliant balloons after everolimus‐eluting stent implantation could provide better clinical outcomes.
Methods:
We randomly assigned 1774 patients with coronary artery disease to undergo additional high‐pressure postdilatation using noncompliant balloons and moderate‐pressure dilatation using stent balloons after everolimus‐eluting stent implantation. The primary endpoint was a composite of death, myocardial infarction (MI), stent thrombosis, and target vessel revascularization (TVR) 2 years after randomization.
Results:
The study was discontinued early owing to slow enrollment. In total, 810 patients (406 patients in the high pressure group and 404 in the moderate pressure group) were finally enrolled. At 2 years, the primary endpoint occurred in 3.6% of patients in the high pressure group and in 4.4% of those in the moderate pressure group (P = .537). In addition, no significant differences were observed between the two groups in the occurrence of an individual end point of death (0.8% in the high pressure group vs 1.5% in the moderate group, P = .304), MI (0.2% vs 0.5%, P = .554), stent thrombosis (0% vs 0.2%, P = .316), or TVR (2.8% vs 2.6%, P = .880).
Conclusions:
The strategy of routine postdilatation using noncompliant balloons after everolimus‐eluting stent implantation did not provide incremental clinical benefits.
- Authorize & License
-
- Files in This Item:
-
Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.